Known Cancer-Pathogen Associations Photo: Bill BransonJames J. Goedert In the 1960s and '70s, as part of a nationwide war on cancer, U.S. virologists took part in a massive effort to find virally caused human cancers. They didn't find much in the way of causative viral agents, but their research did lead to key, high-impact discoveries including the tumor suppressors p53, ras, and myc, not to mention HIV. A profusion of interest in the cancer-causing roles of tumor suppressors, signal transduct
Known Cancer-Pathogen Associations
| Photo: Bill Branson |
 James J. Goedert |
But some contend it's time to return to viruses--to complement the incredible molecular and cell biology insights of the last 20 years with a better knowledge of the role that viruses and other pathogens play in the etiology of human cancers. University of California, San Francisco, professor of medicine Jay Levy, codiscoverer of HIV in 1983, goes so far as to say that there's a ...
Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.
View this Issue
Experts from the Women’s Brain Foundation and bit.bio will explore the importance of sex-specific in vitro models for neurological research and drug discovery.
Discover how scientists are designing the next groundbreaking vaccines against infectious diseases.
In this webinar, Linghua Wang and Jeremy Goecks will talk about technology that enables new approaches for a better understanding of tumors on a cellular, spatial, and environmental level.
Explore how researchers use organoids to understand tissue regeneration and develop novel therapies.
Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces key accreditations in recognition of excellence in data security, AI innovation, and commitment to continuous improvement.
Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) samples.
Tailored nucleic acid extraction and amplification methods help scientists overcome the challenges of detecting Mycoplasma contamination in advanced therapy medicinal products.
